Skip to main content

Advertisement

Table 3 Multivariate analysis of prognostic factors that influence PFS, CSS, and OS

From: Definitive radiotherapy alone over 60 Gy for patients unfit for combined treatment to stage II-III non-small cell lung cancer: retrospective analysis

  PFS CSS OS
Characteristics HR (95 % CI) P-value HR (95 % CI) P-value HR (95 % CI) P-value
Age   0.42   0.32   0.96
 <75 1   1   1  
 ≥75 0.82 (0.51-1.33)   0.70 (0.34-1.42)   1.01 (0.62-1.66)  
Sex   0.66   0.81   0.86
 M 1   1   1  
 F 0.83 (0.35-1.94)   0.86 (0.24-3.08)   1.08 (0.45-2.58)  
ECOG PS   0.27   0.14   0.90
 0-1 1   1   1  
 2-3 1.33 (0.80-2.19)   1.66 (0.84-3.27)   1.56 (0.93-2.60)  
aFEV1(%)   0.63   0.96   0.42
 ≥70 1   1   1  
 <70 0.88 (0.54-1.45)   1.02 (0.52-2.00)   0.81 (0.49-1.34)  
Pathology       
 Squamous cell carcinoma 1   1   1  
 Adenocarcinoma 1.25 (0.56-2.79) 0.59 1.63 (0.62-4.29) 0.32 1.32 (0.60-2.91) 0.49
 Others 0.93 (0.35-2.48) 0.88 0.70 (0.17-2.92) 0.63 0.78 (0.28-2.16) 0.64
Tumor size   0.11   0.50   0.20
<7 c m 1   1   1  
 ≥7 c m 0.60 (0.32-1.11)   0.75 (0.33-1.72)   0.65 (0.34-1.25)  
T-stage   0.02   0.12   0.08
 1-2 1   1   1  
 3-4 2.00 (1.11-3.61)   1.90 (0.85-4.26)   1.67 (0.93-2.98)  
N-stage   0.18   0.30   0.29
 0-1 1   1   1  
 2-3 1.42 (0.85-2.39)   1.46 (0.72-2.97)   1.33 (0.79-2.26)  
Initial response   0.02   0.02   0.07
 CR or PR 1   1   1  
 SD or PD 2.03 (1.15-3.58)   2.40 (1.16-4.98)   1.68 (0.96-2.94)  
  1. Abbreviations: PFS progession-free survival, CSS cause-specific survival, OS overall survival, HR hazard ratio, 95 % CI 95 % confidence interval, ECOG PS Eastern Cooperative Oncology Group performance status, FEV1 forced expiratory volume in one second, CR complete response, PR partial response, SD stable disease, PD progressive disease
  2. aFEV1 test was not performed in 5 patients